Animal model for hepatitis virus infection
AssigneeYeda Research and Development Co. Ltd.
InventorYair Reisner
Life of this patent
Estimating the term…
Abstract
A non-human chimeric animal is obtained by transplanting a non-human mammal host having a T cell deficiency with a human liver tissue preparation or with a liver tissue preparation from a non-human animal capable of being infected by the hepatitis virus (HV). The non-human chimeric animal is useful as an HV model for evaluating anti-HV therapy and prophylaxis.
Claims12
A method for evaluating the potential of an agent or a combination of agents in therapy of a hepatitis virus (HV) infection, comprising:
- (a) providing a chimeric mouse or rat M5 having xenogeneic cells;
- said chimeric mouse or rat M5 being a mouse or rat M1 treated to substantially destroy its hematopoietic cells and then transplanted with hematopoietic cells from one or more mice M2 harboring a defect in T- and B-cell production and transplanted with liver tissue from a xenogeneic mammal M3 of a species capable of being infected by HV;
- the xenogeneic liver tissue in the mouse or rat M5 being infected by HV;
- (b) administering said agent or said combination of agents to said mouse or rat M5;
- and
- (c) evaluating the effectiveness of said agent or said combination of agents in preventing spread of HV infection or reducing its physiological symptoms in said mouse or rat M5.
A method for evaluating the potential of an agent or a combination of agents, in prevention of a hepatitis virus (HV) infection, comprising:
- (a) providing a chimeric mouse or rat M4, being a mouse or rat M1, treated to substantially destroy its hematopoietic cells and then transplanted with hematopoietic cells from one or more mice M2 harboring a defect in T- and B-cell Production and transplanted with non-HV infected liver tissue from a xenogeneic mammal M3 of a species capable of being infected by HV;
- (b) administering said agent or said combination of agents to said mouse or rat M4;
- (c) infecting said mouse or rat M4 with HV;
- and
- (d) evaluating the effectiveness of said agent or said combination of agents in preventing primary HV infection of said xenogeneic liver tissue.
Dependencies are inferred from the claim text.